

Gastroenterology Biologic Drugs

Reference Number: F4963
Date of Response: 28/10/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira – **7 patients**
- Adalimumab Biosimilar – **281 patients**
- Filgotinib – **13 patients**
- Golimumab – **≤5 patients**
- Infliximab – Remicade – **0 patients**
- Infliximab Biosimilar – **205 patients**
- Ozanimod – **0 patients**
- Tofacitinib – **79 patients**
- Ustekinumab – **122 patients**
- Vedolizumab – **131 patients**

Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab – Humira – **≤5 patients**
- Adalimumab Biosimilar – **47 patients**
- Filgotinib – **12 patients**
- Golimumab – **≤5 patients**
- Infliximab – Remicade – **0 patients**
- Infliximab Biosimilar – **90 patients**
- Ozanimod – **0 patients**
- Tofacitinib – **75 patients**
- Ustekinumab – **31 patients**
- Vedolizumab – **107 patients**

≤5. In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.